Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-04-27 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司2021年年度报告
Annual Report Classification · 100% confidence The document is titled '2021 年年度报告' which translates to '2021 Annual Report'. It contains detailed sections typical of an annual report such as company overview, financial data, management discussion and analysis, corporate governance, risk factors, and audited financial statements. The document length is substantial (15,000 characters) and includes comprehensive financial and operational information for the fiscal year 2021. It also mentions the audit report with an unqualified opinion from the accounting firm, which is typical in annual reports. There is no indication that this is merely an announcement or a summary; rather, it is the full annual report itself. FY 2021
2022-04-27 Chinese
科美诊断技术股份有限公司2021年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised through an initial public offering (IPO). It includes specifics on the amount raised, usage of funds, cash management of idle funds, regulatory approvals, and audit opinions from an accounting firm and a sponsoring institution. The content focuses on the company's compliance with regulations regarding the management and use of raised capital, including detailed financial figures and project investment updates. This type of document is typically classified as a Capital/Financing Update (CAP) because it provides comprehensive information about the company's fundraising activities and the subsequent use of those funds, rather than being a full annual report or an earnings release. The document length and detail confirm it is not a mere announcement but a substantive update on capital usage.
2022-04-27 Chinese
中信证券股份有限公司关于科美诊断技术股份有限公司2021年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2021年度持续督导跟踪报告" (2021 Annual Continuous Supervision Tracking Report) issued by a sponsoring institution (中信证券股份有限公司) for a company listed on the STAR Market (科美诊断技术股份有限公司). It details the continuous supervision work, risk factors, financial data, and core competitiveness of the company for the year 2021. The content includes detailed descriptions of supervisory activities, risk disclosures, financial performance, and technical/product advantages. It is a comprehensive report related to ongoing regulatory supervision and company performance rather than a full annual report or quarterly report. The document is not an announcement of a report but the report itself, with substantive content and length (~15,000 characters). It is not an audit report, earnings release, or other categories. The nature of the document aligns with a continuous supervision or tracking report typically issued by a sponsor or underwriter post-IPO to comply with regulatory requirements. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit the other specific categories like Annual Report (10-K) or Interim Report (IR).
2022-04-27 Chinese
科美诊断技术股份有限公司2021年度募集资金存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2021年度募集资金存放与使用情况鉴证报告" which translates to "2021 Annual Fundraising Funds Storage and Usage Verification Report." It is issued by an accounting firm (ShineWing) and includes detailed information about the company's fundraising amount, usage, storage, and management of the raised funds for the year 2021. The document contains specific financial data on fundraising, usage, and cash management, as well as auditor's verification and opinion on the fundraising funds usage. This is a specialized audit or verification report focusing on the use and management of fundraising proceeds, not a full annual report or earnings release. It is not a simple announcement or certification but a standalone audit-type report on fundraising funds usage. Therefore, it fits best under the category Audit Report / Information (AR). The document length (11,957 characters) supports it being a full report rather than a brief announcement. FY 2021
2022-04-27 Chinese
科美诊断技术股份有限公司独立董事关于第一届董事会第十八次会议相关事项的事前认可意见
Regulatory Filings
2022-04-27 Chinese
科美诊断技术股份有限公司独立董事关于公司对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees for the fiscal year 2021. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and confirms no external guarantees were made during the period. The document is a standalone audit-related statement focusing on compliance and risk control related to external guarantees, not a full annual report or financial statement. It is not a report publication announcement or a certification letter but a specific audit-related disclosure. Therefore, it fits best under Audit Report / Information (AR). The document length is short but contains substantive content related to audit and compliance. FY 2021
2022-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.